Valuation: Alector, Inc.

Market Cap 168M 146M 136M 125M 235M 15.98B 240M 1.6B 628M 7.97B 630M 616M 26.28B P/E 2026 *
-1.76x
P/E 2027 * -2.35x
Enterprise Value -79.49M -69.08M -64.49M -59.21M -112M -7.58B -114M -760M -298M -3.78B -299M -292M -12.46B EV / Sales 2026 *
-11.6x
EV / Sales 2027 * -6.94x
Free-Float
86.82%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alector, Inc.

1 month-22.16%
3 months-39.84%
6 months-21.76%
Current year-3.21%
1 week 1.46
Extreme 1.455
1.67
1 month 1.37
Extreme 1.37
2.06
Current year 1.37
Extreme 1.37
2.74
1 year 1.09
Extreme 1.09
3.4
3 years 0.87
Extreme 0.87
9.06
5 years 0.87
Extreme 0.87
29.3
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 71 2013-04-30
Director of Finance/CFO 52 2025-06-19
Chief Tech/Sci/R&D Officer - 2016-12-31
Director TitleAgeSince
Director/Board Member 71 2013-04-30
Director/Board Member 72 2018-09-30
Chairman 77 2023-06-12
Date Insider Type Main position Quantity % Market Cap.
7/9/26 Free

Controller/Auditor

20,000 0.0180%
2/26/26 Sell

Controller/Auditor

4,079 0.0037%
12/5/25 Sell

Controller/Auditor

4,753 0.0044%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-2.58%-77.21% 168M
+0.05%+2.80%+38.17%+74.12% 56.54B
-3.06%-10.22%+23.62%+58.59% 53.6B
+1.84%+1.27%-16.16%-13.50% 22.91B
-0.15%-6.00%-11.50%+344.47% 21.37B
+0.15%-0.77%+23.76%-11.52% 20.27B
-0.67%-1.73%+33.09%-31.09% 17.56B
-1.45%-7.24%+17.67%+563.14% 14.75B
+9.91%+2.64%+188.84%+326.19% 13.53B
+3.83%-1.34%+49.58%+165.22% 13.33B
Average +1.04%-1.49%+34.45%+139.84% 23.4B
Weighted average by Cap. +0.14%-1.70%+31.40%+121.83%

Financials

2026 *2027 *
Net sales 6.86M 5.96M 5.56M 5.11M 9.63M 654M 9.8M 65.6M 25.69M 326M 25.76M 25.19M 1.08B 22.88M 19.89M 18.57M 17.04M 32.14M 2.18B 32.7M 219M 85.74M 1.09B 85.95M 84.04M 3.59B
Net income -94.11M -81.79M -76.36M -70.1M -132M -8.97B -134M -900M -353M -4.47B -353M -346M -14.75B -96.62M -83.97M -78.39M -71.97M -136M -9.21B -138M -924M -362M -4.59B -363M -355M -15.15B
Net Debt -247M -215M -201M -184M -347M -23.56B -353M -2.36B -926M -11.75B -928M -908M -38.75B -326M -284M -265M -243M -458M -31.11B -466M -3.12B -1.22B -15.51B -1.23B -1.2B -51.17B
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
26-08-03 $1.510 0.00% 359,922
26-07-31 $1.510 -6.79% 548,294
26-07-30 $1.620 +6.58% 453,153
26-07-29 $1.520 0.00% 307,858
26-07-28 $1.520 +0.66% 342,803
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.510USD
Average target price
3.100USD
Spread / Average Target
+105.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALEC Stock